Business Context and Reporting Period
Company: Aptevo Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 20, 2025
Event: Filing of a Prospectus Supplement under an existing At-The-Market (ATM) Offering Agreement with Roth Capital Partners, LLC.
Key Financial Metrics
Capital Raise Details:
- Aggregate Offering Price: Up to $8,037,381 for shares of Common Stock.
- Shares Issued to Date: 481,828 shares sold pursuant to the Sales Agreement and Prior Prospectus.
- Gross Proceeds to Date: $3,765,143.
Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report regarding a securities offering.
Material Changes
This filing represents an update to the Company's existing equity offering program. The Prospectus Supplement amends and supplements the Prior Prospectus (filed April 29, 2025, and May 22, 2025) to reflect the continued availability of shares under the Sales Agreement dated April 28, 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company is proceeding with the sale of shares under the ATM agreement. Paul Hastings LLP has issued a legal opinion regarding the shares.
Risks and Contingencies: The filing includes standard disclaimers stating that the 8-K does not constitute an offer to sell or a solicitation of an offer to buy the shares in any jurisdiction where such offer would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the current market price of APVO common stock to assess the valuation of the remaining shares available under the $8,037,381 aggregate offering limit.
- Review the full Prospectus Supplement and the Sales Agreement for specific terms regarding sales agent commissions and underwriting discounts.
- Confirm the Company's current cash position and burn rate to understand the necessity and timing of the remaining capital raise.
- Check for any subsequent filings regarding the actual sale of additional shares beyond the 481,828 shares reported as sold to date.